Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 5, 2011, Pages 463-468

  Conesa Botella, Anali ^a,b   Loembé, Marguerite Massinga ^a   Manabe, Yukari C ^c,d,e   Worodria, William ^c,e   Mazakpwe, Doreen ^c,e   Luzinda, Kenneth ^c,e   Mayanja Kizza, Harriet ^c   Miri, Mitra ^f   Mbabazi, Olive ^c   Koole, Olivier ^a   Kestens, Luc ^a,b   Colebunders, Robert ^a,b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Infectious Diseases Network for Treatment and Research in Africa   (Uganda)

^f YALE UNIVERSITY   (United States)

Author keywords

HAART; HIV; immune reconstitution; lipoarabinomannan; tuberculosis

Indexed keywords

LIPOARABINOMANNAN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; UGANDA; URINE LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIPOPOLYSACCHARIDES; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS; UGANDA;

EID: 81755166353     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31823801de     Document Type: Article

References (21)

1. World Health Organization. Global Tuberculosis Control Report. WHO/HTM/TB/2010.7. Geneva, Switzerland: WHO; 2010.
2. World Health Organization. TB/HIV: A Clinical Manual. WHO/HTM/TB/2004.329. Geneva, Switzerland: WHO; 2004. Available at: http://whqlibdoc.who.int/publications/2004/9241546344.pdf. Accessed October 10, 2011.
3. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet. 2007;369:2042-2049. (Pubitemid 46908825)
4. Daley P, Michael JS, Hmar P, et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis. 2009;13:989-995.
5. Lawn SD, Edwards D, Kranzer K, et al. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS. 2009;23: 1875-1880.
6. Reither K, Saathoff E, Jung J, et al. Low sensitivity of a urine LAMELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis. 2009;9:141.
7. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr. 2009;52:145-151.
8. Mutetwa R, Boehme C, Dimairo M, et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis. 2009;13:1253-1259.
9. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One. 2010;5:e9848.
10. Muller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:251-261.
11. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4:16-21. (Pubitemid 46555247)
12. Manabe YC, Kesavan AK, Lopez-Molina J, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb). 2008;88:187-196.
13. Worodria W, Conesa-Botella A, Kisembo H, et al. Coping with TB immune reconstitution inflammatory syndrome. Expert Rev Respir Med. 2009;3:147-152.
14. Worodria W, Massinga-LoembeM, Luzinda K, et al. for the TB-IRIS Study Group. Incidence and predictors of mortality in a cohort of tuberculosis/HIV co-infected patients commencing antiretroviral therapy. JAIDS. 2011;58: 32-37.
15. World Health Organization. TB-HIV: improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. 2007. Available at: http://whqlibdoc. who.int/hq/2007/WHO-HTM-TB-2007. 379-eng.pdf. Accessed October 10, 2011.
16. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523. (Pubitemid 352005824)
17. Hamasur B, Kallenius G, Svenson SB. A new rapid and simple method for large-scale purification of mycobacterial lipoarabinomannan. FEMS Immunol Med Microbiol. 1999;24:11-17. (Pubitemid 29189211)
18. Chan J, Fan XD, Hunter SW, et al. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun. 1991;59:1755-1761.
19. Boehme C, Molokova E, Minja F, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg. 2005;99:893-900. (Pubitemid 41511449)
20. Abdool Karim SS, Naidoo K, Grobler A. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362: 697-706.
21. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med. 1993;119:177-184. (Pubitemid 23327616)